Homozygous loss-of-function mutation in SIT1 leads to combined immunodeficiency due to dysregulated T-cell receptor signaling
Journal of Allergy and Clinical Immunology · 2026-08 · 158 (2) · 582-597
DOI: 10.1016/j.jaci.2026.03.030 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026-08. Verfasst von Pu Chen und 22 weiteren Autor:innen. Beteiligte Einrichtung: Norwegian Centre for Molecular Biosciences and Medicine (NCMBM), University of Oslo, Oslo, Norway; Institute for Molecular Medicine Finland (FIMM), H…. Hauptthemen laut MEDLINE: Adaptor Proteins, Signal Transducing, Immunologic Deficiency Syndromes, Loss of Function Mutation, Receptors, Antigen, T-Cell. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Norway, Academy of Finland, Nordforsk.
Abstract (Originalsprache)
BACKGROUND: The transmembrane adaptor protein SIT1 (signaling threshold-regulating transmembrane adaptor 1) is a negative regulator of T-cell receptor (TCR) signaling, but its role in human immunity remains poorly characterized. OBJECTIVE: We sought to investigate the molecular consequences of a biallelic loss-of-function SIT1 variant in a patient with combined immune deficiency and recurrent lymphoma. METHODS: Exome sequencing identified the putative disease-causing variant. Immunophenotyping and functional assays were performed on patient-derived lymphocytes and CRISPR-Cas9-mediated SIT1 knockout (KO) T cells from healthy donors. Transcriptomics, proteomics, and super-resolution imaging were used to characterize SIT1 deficiency. RESULTS: The c.236+2T>G variant caused exon 2 skipping and complete SIT1 loss. Patient/KO T cells revealed skewed T-cell subsets, increased activation and proliferation, and impaired CD8+ cytotoxicity. Transcriptomic analysis demonstrated that SIT1 KO upregulated cytokine signaling, metabolic reprogramming, and cell cycle hallmarks. Proteomic analysis confirmed SIT1's association with Src and receptor tyrosine kinases and suggested a novel role for SIT1 in intracellular vesicle trafficking. Imaging revealed SIT1 localized to plasma membrane and TCR microclusters, colocalizing with endolysosomal compartments and linker for activation of T cells. Patient T cells exhibited impaired immune synapse maturation and vesicle accumulation on TCR stimulation. Population data link this rare SIT1 variant to lymphoid malignancy and reduced risk of autoimmunity. CONCLUSIONS: We report the first patient with biallelic loss-of-function SIT1 variant, establishing SIT1 as a critical regulator of T-cell activation, proliferation, and synapse organization, implicating SIT1 deficiency as a novel cause of combined immunodeficiency, predisposing to lymphoid malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Norwegian Centre for Molecular Biosciences and Medicine (NCMBM), University of Oslo, Oslo, Norway; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
- Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; Pediatric Research Center, New Children's Hospital, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland.
- Norwegian Centre for Molecular Biosciences and Medicine (NCMBM), University of Oslo, Oslo, Norway.
- Institute of Biotechnology, University of Helsinki, Helsinki, Finland.
- Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
- Norwegian Centre for Molecular Biosciences and Medicine (NCMBM), University of Oslo, Oslo, Norway; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
Förderung
- Research Council of Norway
- Academy of Finland
- Nordforsk
- South-Eastern Norway Regional Health Authority
- Sigrid Jusélius Foundation
- Austrian Science Fund
- Emil Aaltonen Fundation
- HUS Helsinki University Hospital
Zitieren
APA
Chen, P., Le, K. M., Li, W., Hinrichsen, F., Liu, X., Braathen, R. S., Mamia, N., Szymanska, M., Li, Z., Trotta, L., Almusa, H., Mamia, K., Glumoff, V., Holland, P., Anders, S., Kalinichenko, A., Kaustio, M., Seppänen, M. R. J., Haapaniemi, E. M., …, & Saarela, J. (2026). Homozygous loss-of-function mutation in SIT1 leads to combined immunodeficiency due to dysregulated T-cell receptor signaling. Journal of Allergy and Clinical Immunology, 158(2), 582-597. https://doi.org/10.1016/j.jaci.2026.03.030
Vancouver
Chen P, Le KM, Li W, Hinrichsen F, Liu X, Braathen RS, et al. Homozygous loss-of-function mutation in SIT1 leads to combined immunodeficiency due to dysregulated T-cell receptor signaling. Journal of Allergy and Clinical Immunology. 2026;158(2):582-597. doi:10.1016/j.jaci.2026.03.030
BibTeX
@article{Chen2026,
author = {Chen, Pu and Le, Kim My and Li, Weiwei and Hinrichsen, Francisca and Liu, Xiaonan and Braathen, Ragnhild Selvig and Mamia, Nanni and Szymanska, Monika and Li, Zhuokun and Trotta, Luca and Almusa, Henrikki and Mamia, Katariina and Glumoff, Virpi and Holland, Peter and Anders, Simon and Kalinichenko, Artem and Kaustio, Meri and Seppänen, Mikko R J and Haapaniemi, Emma Maria and Varjosalo, Markku and Martelius, Timi and Grönholm, Juha and Saarela, Janna},
title = {Homozygous loss-of-function mutation in SIT1 leads to combined immunodeficiency due to dysregulated T-cell receptor signaling},
journal = {Journal of Allergy and Clinical Immunology},
year = {2026},
volume = {158},
number = {2},
pages = {582--597},
doi = {10.1016/j.jaci.2026.03.030}
}
EUVIMED